We speculate that EGFR activation, in addition to NRF2 activating mutation or Keap1 dysfunction, might represent a complimentary mechanism for upregulating the serine biosynthetic pathway via NRF2-ATF4 axis in lung cancer. The gene discussed is EGFR; the disease is lung cancer.